ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION
Disclosed in the present application are a salt form and a crystal form of an SIP1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an SIP1 receptor mediated disease or symptom.
1 - 25 . (canceled)
26 . A method of treating and/or preventing an SIP1 receptor mediated disease or condition in a subject in need thereof, comprising administering to the subject a maleate of the compound 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid, having a structure represented by the following formula:
27 . The method of claim 26 , wherein the maleate is substantially a crystal form, wherein with Cu-Kα radiation, the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions: 10.6±0.2°, 16.3±0.2°, 19.5±0.2°, 21.5±0.2°, and 26.9±0.2°.
28 . The method of claim 27 , wherein the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions: 7.0±0.2°, 10.6±0.2°, 13.6±0.2°, 16.3±0.2°, 19.5±0.2°, 20.1±0.2°, 21.5±0.2°, 24.5±0.2°, and 26.9±0.2°.
29 . The method of claim 27 , wherein the crystal form has a Fourier transform infrared spectrum having characteristic peaks at wavenumbers 1734 cm −1 , 1574 cm −1 , 1485 cm −1 , 1439 cm −1 , 1364 cm −1 , 1346 cm −1 , 1080 cm −1 , 1003 cm −1 , 893 cm −1 , 871 cm −1 , 757 cm −1 , and 729 cm −1 .
30 . The method of claim 27 , wherein the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions with relative intensities as follows:
2θ
Relative intensity %
5.3 ± 0.2°
3.4
7.0 ± 0.2°
5.8
10.6 ± 0.2°
100
13.6 ± 0.2°
6.6
14.5 ± 0.2°
3.2
16.3 ± 0.2°
12.2
19.5 ± 0.2°
37.7
20.1 ± 0.2°
8.6
20.7 ± 0.2°
2.8
21.5 ± 0.2°
18.3
24.5 ± 0.2°
11.4
24.7 ± 0.2°
9.6
25.3 ± 0.2°
1.8
26.1 ± 0.2°
1.9
26.9 ± 0.2°
34.5
28.7 ± 0.2°
2.2
31 . The method of claim 27 , wherein the crystal form has an X-ray powder diffraction pattern substantially as illustrated in FIG. 10 .
32 . The method of claim 26 , wherein the maleate is an anhydrate, a hydrate, or a non-solvate.
33 . The method of claim 26 , wherein the S1P1 receptor mediated disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory enteritis, autoimmune diseases, chronic inflammatory diseases, asthma, inflammatory neuropathy, arthritis, transplantation, segmental ileitis, ulcerative colitis, lupus erythematosus, psoriasis, ischemia-reperfusion injury, solid tumors, angiogenesis related diseases, vascular diseases, pain symptoms, acute viral diseases, inflammatory bowel diseases, insulin and non-insulin dependent diabetes mellitus and other related immune diseases.
34 . A method of treating and/or preventing an SIP1 receptor mediated disease or condition in a subject in need thereof, comprising administering to the subject a sodium salt of the compound 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid, having a structure represented by the following formula:
35 . The method of claim 34 , wherein the sodium salt is substantially a crystal form, wherein with Cu-Kα radiation, the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions: 4.4±0.2°, 6.6±0.2°, 14.7±0.2°, and 17.2±0.2°.
36 . The method of claim 35 , wherein the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions with relative intensities as follows:
2θ
Relative intensity %
4.4 ± 0.2°
100
6.6 ± 0.2°
80.8
14.7 ± 0.2°
11.5
15.4 ± 0.2°
2.6
17.2 ± 0.2°
8.6.
37 . The method of claim 35 , wherein the crystal form has an X-ray powder diffraction pattern substantially as illustrated in FIG. 2 .
38 . The method of claim 35 , wherein the crystal form has a Fourier transform infrared spectrum having characteristic peaks at wavenumbers 1560 cm −1 , 1505 cm −1 , 1476 cm −1 , 1417 cm −1 , 1365 cm −1 , 1276 cm −1 , 885 cm −1 , 849 cm −1 , and 756 cm −1 .
39 . The method of claim 34 , wherein the sodium salt is an anhydrate, a hydrate, or a non-solvate.
40 . The method of claim 34 , wherein the SIP1 receptor mediated disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory enteritis, autoimmune diseases, chronic inflammatory diseases, asthma, inflammatory neuropathy, arthritis, transplantation, segmental ileitis, ulcerative colitis, lupus erythematosus, psoriasis, ischemia-reperfusion injury, solid tumors, angiogenesis related diseases, vascular diseases, pain symptoms, acute viral diseases, inflammatory bowel diseases, insulin and non-insulin dependent diabetes mellitus and other related immune diseases.
41 . A method of treating and/or preventing an SIP1 receptor mediated disease or condition in a subject in need thereof, comprising administering to the subject a sulfate of the compound 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid, having a structure represented by the following formula:
42 . The method of claim 41 , wherein the sulfate is substantially a crystal form, wherein with Cu-Kα radiation, the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions: 5.4±0.2°, 8.1±0.2°, 14.8±0.2°, 16.7±0.2°, and 18.3±0.2°.
43 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions: 5.4±0.2°, 8.1±0.2°, 14.8±0.2°, 15.6±0.2°, 16.7±0.2°, 18.3±0.2°, 21.0±0.2°, 22.0±0.2°, 22.9±0.2°, 25.2±0.2°, and 26.3±0.2°.
44 . The method of claim 42 , the crystal form has an X-ray powder diffraction pattern characterized by angle 2θ having characteristic peaks at the following positions with relative intensities as follows:
2θ
Relative intensity %
5.4 ± 0.2°
62.3
8.1 ± 0.2°
47.3
10.9 ± 0.2°
9.9
14.8 ± 0.2°
100
15.6 ± 0.2°
12.5
16.7 ± 0.2°
58.6
18.3 ± 0.2°
18.2
19.7 ± 0.2°
15.5
20.5 ± 0.2°
10.1
21.0 ± 0.2°
17.4
22.0 ± 0.2°
18.1
22.9 ± 0.2°
39.3
25.2 ± 0.2°
37.4
26.3 ± 0.2°
36.5.
45 . The method of claim 41 , wherein the S1P1 receptor mediated disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory enteritis, autoimmune diseases, chronic inflammatory diseases, asthma, inflammatory neuropathy, arthritis, transplantation, segmental ileitis, ulcerative colitis, lupus erythematosus, psoriasis, ischemia-reperfusion injury, solid tumors, angiogenesis related diseases, vascular diseases, pain symptoms, acute viral diseases, inflammatory bowel diseases, insulin and non-insulin dependent diabetes mellitus and other related immune diseases.